Author: Charmaine Fraser

Physiomics plc (AIM: PYC), a leading mathematical modelling company, supporting development of oncology drugs and personalised medicine solutions, is pleased to announce that it has been awarded a grant by Innovate UK and The Office for Life Sciences as part of the UK Government’s Advancing Precision Medicine programme. The grant-funded project is called “PREDICT-ONC: Precision Risk Evaluation and G-CSF Dosing for Chemotherapy-Induced Neutropenia Tool” (the...

10 Nov

Business Update

Physiomics plc (AIM: PYC), is pleased to announce that, following today’s announcement of a significant grant award from Innovate UK and The Office for Life Sciences to support the Company’s personalised dosing programme, Dr Jim Millen and Dr Pete Sargent will provide a business update via Investor Meet Company on 17 November 2023 at 1:00 pm GMT. The presentation is open to all existing and potential...

18 Oct

Notice of AGM

in Other News

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to provide notice of the Company’s Annual General Meeting (“AGM”). The AGM will be held at 10.30 a.m. on 21 November 2023 at the Company’s new registered office, Bee House, 140 Eastern Avenue, Milton Park, Oxfordshire, OX14 4SB. Shareholders will shortly be sent...

17 Oct

News update from Physiomics October 2023

in Blog

Leading mathematical modelling company, supporting oncology drug development. From us to you - curated cutting-edge research and insights. Welcome to our newsletter, where we share the latest updates from Physiomics and offer insights on the pivotal news shaping the dynamic world of drug development. Top news Meet us at AACR-NCI-EORTC! Physiomics is attending the AACR-NCI-EORTC International Conference on Molecular Targets And Cancer Therapeutics at the Hynes Convention Center, Boston on...

03 Oct

Meet our new Chief Operating Officer, Dr Pete Sargent!

in Blog

Pete joins us with experience working for a wide variety of life sciences businesses across R&D and commercial operations, read on to find out why he is excited to join Physiomics and where he sees the most potential! Q: What attracted you to the role at Physiomics? A: “Having worked across the biopharma industry for many years, I’m acutely aware of the mounting pressures drug development companies...

28 Sep

Final Results for the year ended 30 June 2023

20 Sep

Conference Attendance Announcement

in Events

Physiomics plc (AIM: PYC), a leading mathematical modelling company supporting oncology drug development, is pleased to announce that it is attending the AACR-NCI-EORTC International Conference on Molecular Targets And Cancer Therapeutics at the Hynes Convention Center, Boston on 11-15th October 2023. Physiomics will be presenting a poster entitled “Preclinical pharmacokinetic (PK) and tumor growth inhibition (TGI) modeling for mANK-101, an anchored murine interleukin-12 (IL-12) complex for intratumoral...

11 Sep

News update from Physiomics September 2023

in Blog

Leading mathematical modelling company, supporting oncology drug development. From us to you - curated cutting-edge research and insights. Welcome to our newsletter, where we share the latest updates from Physiomics and offer insights on the pivotal news shaping the dynamic world of drug development. Top news Exciting new contract with Numab! We are pleased to announce that we have been awarded a further contract by existing client, Numab Therapeutics. The project...

04 Sep

Senior Management Update